Full Press Release Details
VistaGen Therapeutics Granted U.S. Patent regarding Methods of
Production for AV-101
South San Francisco, CA (December 6, 2017)
Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage
biopharmaceutical company focused on developing new generation
medicines for depression and other central nervous system (CNS)
disorders, today announced the U.S. Patent and Trademark Office
(USPTO) has issued U.S. Patent No.
9,834,801 related to certain methods of production for
AV-101, VistaGen's lead CNS product candidate.
issuance of this U.S. patent by the USPTO advances our intellectual
property strategy for AV-101 at this vital period in its clinical
development. This issued U.S. patent, in conjunction with the
potential issuance of additional AV-101 patent applications
currently under review worldwide, provides VistaGen with added
long-term intellectual property protection for AV-101 and enhances
its commercial potential, stated Shawn Singh, Chief
Executive Officer of VistaGen.
Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage
biopharmaceutical company focused on developing new generation
medicines for depression and other CNS disorders. VistaGen's lead
CNS product candidate, AV-101, is in Phase 2 development, initially
as a new generation oral antidepressant drug candidate for major
depressive disorder (MDD). AV-101's mechanism of
action is fundamentally different from all FDA-approved
antidepressants and atypical antipsychotics used adjunctively to
treat MDD, with potential to drive a paradigm shift towards a new
generation of safer and faster-acting antidepressants. AV-101 is
currently being evaluated by the National Institute of Mental
Health (NIMH) in a small Phase 2 monotherapy study in MDD being
fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr.,
Chief, Section on the Neurobiology and Treatment of Mood Disorders
and Chief of Experimental Therapeutics and Pathophysiology Branch
at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2
study of AV-101 as an adjunctive treatment for MDD patients with an
inadequate response to standard, FDA-approved antidepressants, with
Dr. Maurizio Fava of Harvard University as Principal Investigator.
AV-101 may also have the potential to treat multiple CNS disorders
and neurodegenerative diseases in addition to MDD, including
neuropathic pain, epilepsy, Huntington's disease, Parkinson's
disease levodopa-induced dyskinesia and other disorders where
modulation of the NMDA receptors, activation of the AMPA
neurotransmitter pathways and/or key active metabolites of AV-101
may achieve therapeutic benefit.
more information, please visit www.vistagen.com
and connect with VistaGen on Twitter,
Forward-Looking Statements
The statements in this press release that are not historical facts
may constitute forward-looking statements that are based on current
expectations and are subject to risks and uncertainties that could
cause actual future results to differ materially from those
expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
securing sufficient funding for, and the launch, continuation and
results of the NIMH's Phase 2 (monotherapy) and/or the Company's
planned Phase 2 (adjunctive treatment) clinical studies of AV-101
in MDD, and other CNS diseases and disorders, including neuropathic
pain and PD LID, allowance of patent applications and continued
protection of its intellectual property, and the availability of
substantial additional capital to support its operations, including
the AV-101 Phase 2 adjunctive treatment study and other potential
AV-101 clinical development activities described above. These and
other risks and uncertainties are identified and described in more
detail in VistaGen's filings with the Securities and Exchange
Commission (SEC). These filings are available on the SEC's website
VistaGen undertakes no obligation to publicly update or revise any
forward-looking statements.
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com